Delhi High Courtís Decision in Favor of Cipla Challenged by Roche

by Kathy Jones on  October 11, 2012 at 7:22 PM Medico Legal News
RSS Email Print This Page Comment
Font : A-A+

Delhi High Court's decision to grant relief for Indian pharmaceutical company Cipla by stating that it had not infringed on a drug patent has been challenged by Swiss drug company Hoffmann-La Roche.
 Delhi High Courtís Decision in Favor of Cipla Challenged by Roche
Delhi High Courtís Decision in Favor of Cipla Challenged by Roche

Appealing before the division bench of the high court, Roche sought a stay on the Sep 7 order.

The division bench headed by Justice Ravinder Bhatt, however, recused himself from hearing the plea and transferred the matter to another bench. The matter would come up for hearing Oct 15.

Justice Manmohan Singh had said Roche's patented drug Erlotinib Hydrochloride, promoted under the brand TARCEVA, is also valid like Cipla's cancer drug promoted under the trade name ERLOCIP.

Roche had filed the plea accusing Cipla of manufacturing and marketing the cancer drug under the trade name ERLOCIP, which it claimed was the generic version of its patented drug Erlotinib Hydrochloride, promoted under the brand TARCEVA.

Both the drugs are used to cure ailments like lung cancer and pancreatic cancer.

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive